204 results about "P. multocida" patented technology

The present invention relates to methodology for polymer grafting by a polysaccharide synthase and, more particularly, polymer grafting using the hyaluronate synthase from Pasteurella multocida.

The present invention relates to methodology for polymer grafting by a polysaccharide synthase and, more particularly, polymer grafting using the hyaluronate or chondroitin or heparin/heparosan synthases from Pasteurella multocida, in order to create a variety of glycosaminoglycan oligosaccharides having a natural or chimeric or hybrid sugar structure.

The invention discloses a rabbit triple inactivated vaccine, a preparation method and the application thereof; the rabbit triple inactivated vaccine is formed mainly by rabbit hemorrhagic disease virus liquid which is inactivated and detoxified, rabbit pasteurella multocida liquid and rapid A type clostridium perfringens liquid which have 1:1:2 volume ratio; in the invention, by optimizing culture technology, concentration technology and immunizing dose and other measures, the rabbit triple inactivated vaccine which has good immunity effect and safety is obtained and can effectively control the rabbit hemorrhagic disease, the pasteurella multocida disease and the pasteurella multocida disease (A type) and reduce vaccine injection times of farmers, so as to reduce the stress reaction of animals and improve the production performance. The clinical application proves that the immunization effect of the rabbit triple inactivated vaccine is ideal, each rabbit is vaccinated with 2ml and has immunity after 5-7 days, the immune period is at least 180 days, and the immune safety is good without toxic and side effect.

The invention provides a polyvalent inactivity vaccine for preventing and treating atrophic rhinitis of a swine and a preparation method thereof. The polyvalent inactivity vaccine contains inactivated Bordetella bronchiseptica, Pasteurella multocida A, Pasteurella multocida D and PMT (Pasteurella Multocida Toxin) anatoxin. The invention further provides a novel method for culturing and extractingPMT. Compared with the traditional atrophic rhinitis of the swine, the polyvalent inactivity vaccine for the atrophic rhinitis of the swine, provided by the invention, can be used for more generally and effectively treating and preventing the atrophic rhinitis of the swine by comprehensive antigen protection. Finally, in the polyvalent vaccine provided by the invention, the vaccine with a plurality of antigens in a reasonable proportion can be used for solving the problem that the plurality of the antigens interfere each other, thereby improving an immune effect. Furthermore, the inventor provides a water adjuvant by which defects such as incomplete absorption, large side reaction and the like after the traditional alumina gel adjuvant, Freund adjuvant and water-in-oil adjuvant are injected into the water adjuvant can be overcome.

The invention discloses bacillus subtilis AP139 and fermented microbial inoculum thereof, and an application method of the bacillus subtilis AP139 and the fermented microbial inoculum. The bacillus subtilis is preserved in the China Center For Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: M2014053. The bacterial strain can restrain the growth and the propagation of porcine toxigenic pasteurella multocida in a culture dish experiment by screening porcine toxigenic pasteurella multocida resistance. The bacillus subtilis AP139 is atomized in an animal breeding shed, the bacillus subtilis AP139 has an obvious characteristic of restraining the growth of pasteurella multocida in air, the pasteurella multocida attack rate in a breeding farm is reduced, at the same time, the bacillus subtilis AP139 also has a good effect on restraining escherichia coli, staphylococcus aureus and salmonella, and the bacillus subtilis AP139 has a favorable application prospect.

The present invention relates to a nucleic acid segment having a coding region segment encoding enzymatically active Pasteurella multocida hyaluronate synthase (PmHAS), and to the use of this nucleic acid segment in the preparation of recombinant cells which produce hyaluronate synthase and its hyaluronic acid product.

The present invention relates to methodology for polymer grafting by a polysaccharide synthase and, more particularly, polymer grafting using the hyaluronate synthase from Pasteurella multocida. The present invention also relates to coatings for biomaterials wherein the coatings provide protective properties to the biomaterial and/or act as a bioadhesive. Such coatings could be applied to electrical devices, sensors, catheters and any device which may be contemplated for use within a mammal. The present invention further relates to drug delivery matrices which are biocompatible and may comprise combinations of a biomaterial or a bioadhesive and a medicament or a medicament-containing liposome. The biomaterial and/or bioadhesive is a hyaluronic acid polymer produced by a hyaluronate synthase from Pasteurella multocida. The present invention also relates to the creation of chimeric molecules containing hyaluronic acid or hyaluronic acid-like chains attached to various compounds and especially carbohydrates or hydroxyl containing substances. The present invention also relates to a chondroitan synthase from Pasteurella multocida which is capable of producing polysaccharide polymers on an acceptor or primer molecule.

The invention provides an inactivated vaccine for streptococcus suis and pasteurella multocida diseases and a preparation method thereof, which can prevent streptococcus suis infection caused by a plurality of different sero-group streptococcus and infection caused by a plurality of different capsular serotype pasteurella multocida, achieves multiple preventions with one injection clinically, and is lowered in cost, free from the hidden hazard of virus dispersion, safe and reliable. The invention further provides a method for preparing the inactivated vaccine for streptococcus suis and pasteurella multocida diseases.

Disclosed is the animal vaccine for the prevention, treatment and detection of pig progressive atrophic rhinitis, which comprises three polypeptides generated by antibody against Pasteurella multocida related to progressive atrophic rhinitis, these polypeptides all have a amino acid sequence, which mainly corresponds to the 2-486, 486-986 or 986-1281 amino acid residue of the PMT protein. The invention also discloses the multivalent vaccine for the prevention and treatment of at least PAR for animals.

The invention relates to a rabbit hemorrhagic disease virus baculovirus vector and pasteurella multocida bivalent inactivated vaccine and a preparation method thereof, and belongs to the field of immune technology. Recombinant rabbit hemorrhagic disease virus VP60 baculovirus is inoculated into Sf9 insect cells and cultured at 27-28 DEG C. When cell lesion reaches 85% or more, a cell culture is harvested and inactivated, and the inactivated cell culture is used as a rabbit hemorrhagic disease virus antigen. Rabbit Pasteurella multocida capsular serotype A C51-17 strain is amplified and cultured, a bacterial solution is inactivated, and the inactivated bacterial solution is used as a Pasteurella multocida antigen. The rabbit hemorrhagic disease virus baculovirus vector and pasteurella multocida bivalent inactivated vaccine can be prepared by mixing the rabbit hemorrhagic disease virus antigen and the Pasteurella multocida antigen with adjuvants in proportion. The rabbit hemorrhagic disease virus baculovirus vector and pasteurella multocida bivalent inactivated vaccine has high safety, good immune effect and simple process, and can be used for preventing and controlling Rabbit Hemorrhagic Disease (Rabbit Plague) and Rabbit Pasteurella multocida.

The invention discloses primers, probes and a kit for rapidly detecting mycoplasma bovis on site. The kit comprises a forward primer sequence shown as SEQ No.1, a reverse primer sequence shown as SEQ No.2, and a probe sequence shown as SEQ No.3, wherein the 5'-terminal of the reverse primer sequence is labeled by biotin; the 5'-terminal of the probe sequence is labeled by FAM, dSpacer is arranged at the position away from the 5'-terminal by 30 basic groups, and the 3'-terminal is blocked by C3-spacer. The primers, the probe assembly and the kit for detecting the mycoplasma bovis RPA-nfo are high in sensitivity and strong in specificity, the mycoplasma bovis DNA of 10 copies/reaction can be detected at the minimum, and the primers and the probes for detecting RPA-nfo respectively have no cross reaction with other mycoplasmas, as well as the bacteria including pasteurella multocida, mannheimia haemolytica, arcanobacterium pyogenes, histophilus somni, and streptococcus pneumoniae.

A conserved inner-core oligosaccharide epitope expressed on the lipopolysaccharide (LPS) of a range of disease causing pathogenic bacterial isolates, including Actinobacillus pleuropneumoniae (Ap), Mannheimia haemolytica (Mh) and Pasteurella multocida (Pm), is disclosed. Construction of a mutant bacterial strain exclusively expressing the conserved inner core OS epitope as a terminally exposed structure has allowed the identification, production and isolation of an inner core LPS which is common to all three organisms. Further provided are associated vaccines, antibodies raised against the conserved LPS inner core and glycoconjugates comprising the LPS inner core linked to an immunogenic carrier.

The invention provides a vaccine composition, and the vaccine composition comprises immunization amount of a bordetella bronchiseptica antigen, immunization amount of pasteurella multocida toxoid antigen and an adjuvant acceptable in veterinary medicine. The vaccine composition is capable of effectively controlling co-infected swine atrophic rhinitis caused by bordetella bronchiseptica and pasteurella multocida, and further comprises other antigen compositions for controlling respiratory syndrome caused by secondary infection of swine atrophic rhinitis. By reducing the antigen composition and using pasteurella multocida toxoid to replace pasteurella multocida antigens with different serotypes, the purpose of preventing swine atrophic rhinitis is realized. Also by improving the antigen content in per volume of the vaccine composition, the immunization dosage of the vaccine composition is reduced to 1/4 of the dosage of a conventional vaccine without reducing the immunization effect. Therefore, the vaccine composition is relatively low in immunization dosage, relatively less in antigen compositions, relatively low in immunization cost and convenient to use.

The invention discloses a geotechnical material of microbial granule and a production method thereof. The material comprises, by weight, 1-5 parts of foam plastic particles or fragments, 80-95 parts of calcareous soil and 5-9 parts of Pasteurella multocida fluid. The geotechnical material prepared by the method has the advantages of being light in mass, medium in strength, and good in stability. The geotechnical material of microbial granule can be produced by using discarded foam material and calcareous material, thus the cost is low. The geotechnical material can be used as the filler material for man-made islands of roadbed and pipe, and can also be used for preparing building materials such as light building blocks.

The invention discloses a treble PCR method for simultaneously detecting mycoplasma hyopneumoniae, porcine pasteurella multocida and haemophilus parasuis. A treble PCR detection method for directly detecting 3 pathogens once from a sample is established through the following steps: firstly, screening out conservative genetic fragments with the gene type characteristics of the pathogens, using the conservative genetic fragments as 3 gene target points for PCR detection, respectively synthetizing and amplifying primers of the target point genes, and then putting 3 pairs of the primers of the 3 genetic fragments in a PCR reaction system. Through the adoption of the treble PCR method disclosed by the invention, on one hand, the pathogens can be accurately detected, and a mixed infection condition can be analyzed, so that the epidemic and development trend of an epidemic situation can be controlled, and the treble PCR method has double effects; on the other hand, compared with the conventional PCR method, the detecting time is shortened by 24 hours, so that the purpose of quickly detecting actual samples is achieved, and the cost is reduced.

The invention discloses an indirect ELISA (enzyme-linked immuno sorbent assay) detection reagent kit and a detection method for bovine-derived pasteurella multocida antibodies. The indirect ELISA detection reagent kit comprises solid-phase carriers enveloped by bovine-derived pasteurella multocida specific protein 0230, HRP (horse radish peroxidase)-labeled IgG (immunoglobulin G) enzyme-labeled second antibodies, standard positive control serum, standard negative control serum, sample diluent, concentrated washing solution, color developing solution and stop solution. The detection method is implemented by the aid of the indirect ELISA detection reagent kit, and includes enabling to-be-detected serum samples to be in contact with the enveloping bovine-derived pasteurella multocida specific protein 0230 on the solid-phase carriers and carrying out heat-insulation incubation; specifically capturing specific antibodies combined on 0230 protein antigens by the aid of the HRP-labeled IgG enzyme-labeled secondary antibodies; developing colors by the aid of color developing agents so as to measure 0230 protein antibody level of the to-be-detected serum samples. The indirect ELISA detection reagent kit and the detection method have the advantages of good specificity and repeatability, high sensitivity and the like.

The invention belongs to the technical field of veterinary drug preparation, and relates to a compound doxycycline-hydrochloride florfenicol sustained-release microsphere suspension injection for veterinary use. The suspension injection is produced through a preparation technology combining an inclusion technology, a microcapsule technology and a high-pressure homogenization technology. The suspension injection comprises the following ingredients according to W/V: 10-30% of an inclusion material, 5-20% of doxycycline hydrochloride, 5-20% of florfenicol, 2.5-7.5% of a high-molecular capsule material, 0.2-1% of a suspending agent, 0.25-1% of an anti-oxidant, 0.05-0.2% of a metal chelator, 0.1-0.4% of an antiseptic, and the balance injection water. The active ingredients in the injection possess synergic antibacterial effects and obvious sustained release effect, clinic dosing frequency is reduced, the injection does not contain organic solvents, does not stimulate target animals, is small in toxic and side effects, and is capable of controlling respiratory diseases caused by streptococcus suis, actinobacillus pleuropneumoniae, pasteurella multocida, haemophilus parasuis, mycoplasma and the like.